Evidence map›Paper›PMID 26642907›Full record

Trial reportThe American journal of medicine2016

Warfarin Dosing Algorithms and the Need for Human Intervention.

Scott E Kasner, Le Wang, Benjamin French, Steven R Messé, Jonas Ellenberg, Stephen E Kimmel, COAG Trial Steering Committee

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal of medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Personalized medicine in cardiovascular disease: review of literature.Journal of diabetes and metabolic disorders · 2021
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Scott E KasnerDepartment of Neurology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia. Electronic address: kasner@mail.med.upenn.edu.
Le WangDepartment of Neurology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia.
Benjamin FrenchDepartment of Neurology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia.
Steven R MesséDepartment of Neurology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia.
Jonas EllenbergDepartment of Neurology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia.
Stephen E KimmelDepartment of Neurology and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia.
COAG Trial Steering Committee

Funding

NHLBI NIH HHS HHSN268200800003CPHS HHS HHSN-268200800003C
6 · The paper itself

Abstract

backgroundDosing algorithms for warfarin incorporate clinical and genetic factors, but human intervention to overrule algorithm-based dosing may occasionally be required. The frequency and reasons for varying from algorithmic warfarin management have not been well studied.

methodsWe analyzed a prospective cohort of 1015 participants from the Clarification of Optimal Anticoagulation through Genetics trial who were randomized to either pharmacogenetic- or clinically-guided warfarin dosing algorithms. Clinicians and participants were blinded to dose but not international normalized ratio (INR) during the first 28 days. If an issue arose that raised concern for clinicians but might not be adequately accounted for by the protocol, then clinicians contacted the unblinded medical monitor who could approve exceptions if clinically justified. All granted exceptions were logged and categorized. We analyzed the relationships between dosing exceptions and both baseline characteristics and the outcome of percentage of time in the therapeutic INR range during the first 4 weeks.

resultsSixteen percent of participants required at least one exception to the protocol-defined warfarin dose (15% in the genotype arm and 17% in the clinical arm). Ninety percent of dose exceptions occurred after the first 5 days of dosing. The only baseline characteristic associated with dose exceptions was congestive heart failure (odds ratio 2.12, 95% confidence interval, 1.49-3.02, P <.001). Neither study arm nor genotype was associated with dose exceptions.

conclusionDespite rigorous algorithms, human intervention is frequently employed in the early management of warfarin dosing. Congestive heart failure at baseline appears to predict early exceptions to standardized protocol management.

Indexed as

AlgorithmsAdultAgedAnticoagulantsBiomarkers, PharmacologicalFemaleHumansInternational Normalized RatioMaleMiddle AgedPharmacogeneticsWarfarinAnticoagulantsBiomarkers, PharmacologicalWarfarinAnticoagulantsCongestive heart failurePharmacogenomicsWarfarin

Identifiers

PMID26642907
PMCPMC4792751

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.